Randomized, double-blind, placebo-controlled, single and multiple ascending dose (SAD and MAD) trial conducted by Simbec Research Ltd., U.K.
Trial
A Two-part, Randomized, Double-blind, Placebo-controlled, First-In-Human, Phase I Study of the Safety, Tolerability, and Pharmacokinetics of SPR720 Following Administration of Single and Multiple Ascending Oral Doses in Healthy Volunteers
Overview
Developer Associations
Compound Associations